18 completed, 5 terminated, 2 withdrawn, 1 unknown. 26 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 18, Terminated 5, Withdrawn 2, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Urinary Incontinence, Urge: new trials by email Literature Review of Urinary Incontinence, Urge trials Research Report on Urinary Incontinence, Urge
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Alkalinized Lidocaine, Placebo Sodium Chloride 0.9% Inj - Urge Incontinence, Overactive Bladder | Phase 3 | Unknown | Herlev and Gentofte Hospital | 50 | 2022-09-12 | 2022-09-22 |
| Sling vs Botox for Mixed Incontinence Botox® injection, Mid-urethral sling - Urinary Incontinence, Stress, Urinary Incontinence, Urge | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 150 | 2020-06-08 | 2025-06-03 |
| An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 506 | 2018-06-14 | 2021-03-18 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1530 | 2018-03-26 | 2021-03-04 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| Combined Treatment for Mixed Incontinence Miduretheral Sling, Miduretheral Sling with behavioral/pelvic floor therapy - Urinary Incontinence, Stress, Urinary Incontinence, Urge | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 480 | 2013-10-28 | 2020-05-14 |
| Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) Fesoterodine Fumarate - Urge Urinary Incontinence | Phase 3 | Completed | University of North Carolina, Chapel Hill | 61 | 2012-09-01 | 2020-03-18 |
| Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) InterStim® device, Botox® injection - Urinary Incontinence, Urge | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 386 | 2012-02-01 | 2018-05-02 |
| Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder Electrical Field Stimulation Device, Sham Nerve Stimulation Device - Urinary Incontinence, Urge | Phase 3 | Terminated | EMKinetics, Inc | 130 | 2011-10-01 | 2013-01-31 |
| Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence Transcutaneous mechanical nerve stimulation - Stress Urinary Incontinence, Urge Urinary Incontinence | Phase 3 | Terminated | Copenhagen University Hospital at Herlev | 4 | 2011-05-01 | 2013-05-24 |
| Anticholinergic vs. Botox Comparison Study Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg - Urge Urinary Incontinence, Overactive Bladder | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 249 | 2010-03-01 | 2018-05-02 |
| Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder Propiverine Hydrochloride, Tolterodine Extended-release Tablet - Overactive Bladder | Phase 3 | Completed | Lee's Pharmaceutical Limited | 324 | 2010-01-01 | 2012-01-25 |
| A Study of YM178 in Subjects With Symptoms of Overactive Bladder YM178, Placebo, tolterodine ER - Urinary Bladder, Overactive | Phase 3 | Completed | Astellas Pharma Inc | 1126 | 2009-12-21 | 2024-10-31 |
| A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder YM178, Placebo, tolterodine - Urinary Bladder, Overactive | Phase 3 | Completed | Astellas Pharma Inc | 1139 | 2009-07-24 | 2024-10-31 |
| Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence Oxybutynin, Placebo - Urge Urinary Incontinence, Urinary Frequency | Phase 3 | Completed | Antares Pharma Inc. | 626 | 2009-03-01 | 2014-07-02 |
| Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark) - Urinary Incontinence | Phase 3 | Withdrawn | Copenhagen University Hospital at Herlev | 2008-08-01 | 2012-02-24 | |
| Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Mirabegron, Tolterodine, Placebo to Mirabegron - Urinary Bladder, Overactive | Phase 3 | Completed | Astellas Pharma Inc | 2336 | 2008-04-28 | 2024-11-20 |
| Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Mirabegron, Tolterodine, Placebo to Mirabegron - Urinary Bladder, Overactive | Phase 3 | Completed | Astellas Pharma Inc | 2792 | 2008-04-25 | 2024-11-20 |
| Over Active Bladder Instillation Study - Botox Botox Instillation, DMSO Instillation - Overactive Bladder, Urinary Urge Incontinence | Phase 3 | Terminated | Mayo Clinic | 25 | 2008-04-01 | 2014-07-11 |
Showing 20 of 26. Sign in to see all of them.
Urinary Bladder, Overactive (18) · Urinary Incontinence (11) · Urinary Incontinence, Stress (4) · Lower Urinary Tract Symptoms (2) · Urologic Diseases (2) · Hematuria (1) · Pain, Procedural (1) · Urinary Tract Infections (1)
Female Urogenital Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (26) · Male Urogenital Diseases (26) · Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (26) · Urination Disorders (26) · Urogenital Diseases (26) · Urological Manifestations (26) · Lower Urinary Tract Symptoms (24) · Urologic Diseases (24) · Urinary Bladder Diseases (18) · Urinary Incontinence (15) · Hemorrhage (1) · Infections (1) · Neurologic Manifestations (1)
Tolterodine Tartrate (9) · Botulinum Toxins, Type A (5) · mirabegron (5) · oxybutynin (3) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (2) · ritobegron ethyl (2) · Dimethyl Sulfoxide (1) · Solifenacin Succinate (1) · Suburethral Slings (1) · fesoterodine (1) · imidafenacin (1) · propiverine (1) · trospium chloride (1)
Astellas Pharma Inc (5) · NICHD Pelvic Floor Disorders Network (4) · Copenhagen University Hospital at Herlev (2) · Kissei Pharmaceutical Co., Ltd. (2) · Urovant Sciences GmbH (2) · Alza Corporation, DE, USA (1) · Antares Pharma Inc. (1) · EMKinetics, Inc (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Herlev and Gentofte Hospital (1) · Lee's Pharmaceutical Limited (1) · Mayo Clinic (1) · R-Pharm (1) · University of North Carolina, Chapel Hill (1) · University of Zurich (1)
United States (14) · Denmark (5) · Canada (3) · Hungary (3) · Japan (3) · Latvia (3) · Lithuania (3) · Poland (3) · Russia (3) · Switzerland (3) · Australia (2) · Austria (2) · Belarus (2) · Belgium (2) · China (2)
Yasuhiro Omori (2) · Anthony Visco, MD (1) · Benjamin Li, PhD (1) · Cindy Amundsen, MD (1) · Deborah L. Myers, MD (1) · Dennis Wallace (1) · Dennis Wallace, PhD (1) · Heidi S Harvey, MD (1) · Holly Richter, PhD, MD (1) · Jennifer M Wu, MD (1) · Jens R Sonksen, MD, Ph.D (1) · Jerry Lowder, MD (1)
PMID 37160401, PMID 24246044, PMID 33620895, PMID 18499184, PMID 19233423, PMID 22008247, PMID 23036134, PMID 23218404, PMID 24486637, PMID 26516810, PMID 27564385, PMID 29031894, PMID 31211964, PMID 31529007, PMID 31895722, PMID 32769647, PMID 33332699, PMID 33356445, PMID 33469832, PMID 34237755, PMID 34242627, PMID 34297969, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052, PMID 37586057, PMID 38212101, PMID 38651909, PMID 39797697, PMID 40323617
2017 (2), U01HD069031 (2), U10HD041261 (2), U10HD041267 (2), U10HD054214 (2), U10HD054215 (2), R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041263 (1), U10HD054136 (1), U10HD054241 (1), U10HD069010 (1), U10HD069013 (1), U10HD069025 (1)